Medicine is moving to the mRNA model that is patented and personalized. The global market for mRNA therapeutics is expected to grow from $46.7 billion in 2021 to $101.3 billion by 2026.
"Australia’s RNA sector was recently bolstered by the Government’s 10-year strategic partnership with Moderna and the Victorian Government to establish an onshore mRNA manufacturing facility in Melbourne.
The Victorian, New South Wales, Queensland and South Australian governments are also actively investing in the RNA sector.
The Government is also targeting $1.5 billion through the National Reconstruction Fund (NRF) for medical manufacturing, $1 billion for advanced manufacturing and a further $1 billion for critical technologies – sectors that can include biotechnologies.
Biotechnologies are also one of the seven key enabling technologies in the Australian Government’s Critical Technologies List.
DISR’s consultation is open until 16 October 2023, and the discussion paper is available at https://consult.industry.gov.au/rnaplan
"There is a tsunami of mRNA medicines coming" Melissa J Moore, PhD and Chief Health Officer for Moderna.
With currently 175 clinic trials of mRNA based medicine and 54 waiting in the wings, this technology can be injected to grow new blood vessels in the heart, treat cancer patients with personalized cancer vaccines that attack cancer cells and be used to treat metabolic and genetic diseases.
Melissa goes on to discuss how revolutionary it was that they were able to design a vaccine
• 10 min read